Pioneer REYON, Opening a New Paradigm
R&D Pipeline
R&D Pipeline
Co-development R&D
  • Antibody drugs
    - Other degenerative brain diseases such as Alzheimer's
  • AAV vector-based gene therapy
    AAV 벡터 기반 유전자 치료제
    - Acute neurological disease and neurodegenerative disease, etc.
  • Gene therapy platform technology
    유전자 치료제 플랫폼 기술
    - Gene transfer and increased expression in vivo
    - Co-development of ElectroPorator
    유전자 치료제 플랫폼 기술
    - Patented technology for gene transfer and increased expression in vivo
    - Development and production of normal human cell lines for biopharmaceutical research/production
  • Gene therapy drugs
    AAV 벡터 기반 유전자 치료제
    - Chronic renal failure and ischemic heart disease
    pDNA 유전자 치료제
    - Liver fibrosis & cirrhosis
    - Co-development & Agreement of production and supply for non-clinical test material
  • mRNA-based Virus Vaccine & Gene Therapy
    mRNA 백신 및 치료제
    - Co-development of mRNA therapeutics delivered on CDVs for antivirus vaccines and rare genetic disease therapies using MDimune’s proprietary BioDrone® platform technology based on CDVs.
  • mRNA Vaccine & follow-up pipeline
    mRNA 백신/후속 파이프라인
    - MOU for co-development of clinical and commercial production for COVID-19 mRNA vaccine and follow-up pipeline
  • Bacteriophage
    - MOU for co-development of PHAGERUS® vaccine platform and commercialization for human influenza, avian influenza, G4 virus and etc.
  • PDRN
    - Tissue regeneration (95% similar to human DNA)/PDRN-based specialty drug development and commercialization
  • Natural medicine, health functional food
    천연물의약품, 건강기능식품
    - Promoting new development through strategic cooperation between REYON Pharmaceutical, FINZELBERG, and G&P for various indications
  • Antifungal Drug
    - Technical transfer of a patented technology of antifungal agent ‘iN-EYD’ of the new mechanism of action